среда, 30 ноября 2016 г.

Galectin Therapeutics Inc. (GALT) Stock Rating Lowered by Zacks Investment Research

Galectin Therapeutics Inc. (GALT) Stock Rating Lowered by Zacks Investment Research


According to Zacks, "Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function.



from Biotech News